Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

Sickle Cell Disease clinical trials near you

A clinical trial is a research study that tests whether a treatment is safe and works. Taking part is always your choice, and you can stop at any time. Listing a study here is not a recommendation — talk it through with your own team.

138 recruiting studiesFrom ClinicalTrials.gov (opens in a new tab)

Trial results

8 shown of 138

8 shown of 138 clinical trials.

  1. RecruitingInterventionalNCT06725550

    Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

    Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy

    The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

    Sites
    1
    Target
    120
    Study sites
    Cincinnati, US

    Sponsor: University of Cincinnati

  2. RecruitingInterventionalNCT06691867

    Integrative Training Program for Pediatric Sickle Cell Pain

    Sickle Cell Disease

    This research aims to answer the question: does a group training program specifically for teens with chronic sickle cell disease (SCD) pain that teaches skills to strengthen the mind and body help improve everyday functioning and reduce pain symptoms? The program will be tailored to address challenges related to frequent or chronic sickle cell pain and may improve participants' physical and emotional health. The program, called I-STRONG for SCD (Integrative Strong Body and Mind Training for Sickle Cell Disease), may help improve everyday functioning and pain symptoms in teens with chronic pain related to SCD. The research team aims to determine how participants (teens and parents) respond to this program.

    Sites
    4
    Target
    155
    Study sites
    Hartford, US +3 more

    Sponsor: Emory University

  3. RecruitingPhase 2InterventionalNCT06635902

    Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

    Sickle Cell Disease, Vaso-occlusive Pain Episode

    The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain. Participants will: * Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay * After hospital discharge, visit the clinic in about 30 days for checkup and tests

    Sites
    1
    Target
    99
    Study sites
    Washington D.C., US

    Sponsor: Suvankar Majumdar

  4. RecruitingPhase 1, Phase 2InterventionalNCT06399107

    Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

    Sickle Cell Disease, Sickle-Cell Disease with Crisis

    This study is an open-label, non-randomized, single-dose Phase 1/2 trial involving around 85 adult and pediatric participants aged between 2 and 50 years with sickle cell disease (SCD). It aims to assess the effectiveness of hematopoietic stem cell transplantation (HSCT) using BAH243 for SCD.

    Sites
    1
    Target
    85
    Study sites
    Beijing, CN

    Sponsor: Essen Biotech

  5. RecruitingPhase 3InterventionalNCT07274254

    Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease

    Vaso-Occlusive Pain Episode in Sickle Cell Disease

    The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.

    Sites
    12
    Target
    104
    Study sites
    Bordeaux, FR +11 more

    Sponsor: Nantes University Hospital

  6. RecruitingInterventionalNCT06823219

    Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.

    Sickle Cell Disease

    Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle. However, recent findings demonstrated in the first randomised, controlled, and prospective study implementing endurance training in SCD that, when adequately calibrated, regular moderate-intensity endurance training is not only safe but also beneficial for patients (primary outcome: improvement of physical ability). This pivotal randomised, controlled, prospective study is designed to prove, on a large multicentre cohort, adult and paediatric, including patients with complications and over a longer period (one year). The objective of the study is to demonstrate the efficacy of participating in a program of regular physical activity to reduce the rate of vaso-occlusive crises requiring hospitalisation and to improve physical ability in patients with SCD.

    Sites
    1
    Target
    120
    Study sites
    Créteil, FR

    Sponsor: Assistance Publique - Hôpitaux de Paris

  7. RecruitingInterventionalNCT06318143

    mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria

    Sickle Cell Disease

    Large knowledge gaps remain regarding strategies to promote the adoption of hydroxyurea (HU), particularly in sub-Saharan African countries including Nigeria, where more than 75% of annual sickle cell anemia births occur. The vast majority of people with SCD in Africa do not receive evidenced-based health care (e.g., newborn screening, health education, prophylaxis for infection, optimal nutrition and hydration, blood transfusion, transcranial Doppler screening, and HU therapy), despite its effectiveness in reducing SCD-related adverse outcomes and mortality. The use of HU in SSA is \

    Sites
    1
    Target
    900
    Study sites
    Abuja, NG

    Sponsor: New York University

  8. RecruitingPhase 1InterventionalNCT07226219

    Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

    Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)

    The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among caregivers.

    Sites
    1
    Target
    72
    Study sites
    Memphis, US

    Sponsor: St. Jude Children's Research Hospital